Entelos inks deal with Lilly

July 10, 2008 — 11:55am ET | By John Carroll

Elan hires ex-Lilly exec Paya as new prez
ALSO NOTED: MonoSol Rx sets IPO; Entelos buys Iconix; and much more...
Eli Lilly in talks to buy ImClone
Genentech teams with Glycart on antibody program
Eli Lilly to buy ImClone for $6.5 billion
Lilly CEO defends 'risky' ImClone buyout
Daiichi, Lilly: still no word on prasugrel
Lilly, Glenmark suspend osteoporosis trial
Lilly inks data management deal with Icon
United Therapeutics' stock plunges on trial failure

Tools

Email
Print
Comment
Contact Author

Shares of the UK's Entelos surged after the company reported a licensing pact with Eli Lilly. The pact covers access to Entelos' database of 630 drug profiles, which is used to test an experimental therapy's safety and toxicity. Report

Be the first to comment

Comments

Post new comment

Paid Research Reports

RNA therapy: the next big thing after monoclonal antibodies?
Biotech M&A Strategies: Deal assessments, trends and future prospects
The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
Sales Force Effectiveness

Most Popular Stories

Featured Jobs

Webinars

Popular Topics

Events

Entelos inks deal with Lilly

Related Stories

Comments

Post new comment

Paid Research Reports

THE FIERCEMARKETS NETWORK